Der er evidens for brug af cannabinoider til symptomatisk behandling af multipel sklerose
Sammanfattning
We identified 16 randomized placebo-controlled trials investigating cannabinoids as symptomatic treatment in multiple sclerosis (MS). There is evidence
that nabiximols oromucosal spray may reduce subjective symptoms of spasticity and that dronabinol is effective against neuropathic pain in patients with MS.
The existing treatment system in Denmark is in conformity with the existing data and there is not sufficient evidence to modify it.